Levodopa/Carbidopa Monohydrate Axcount (Levodopa, Carbidopa Monohydrate)

Levodopa is a precursor of dopamine that crosses the blood‑brain barrier. Once inside the central nervous system, it is converted to dopamine, replenishing the depleted neurotransmitter that is characteristic of Parkinson's disease. Carbidopa prevents this conversion in the periphery, allowing more levodopa to reach the brain.

The exact dose is individualized and set by the prescribing clinician based on the patient’s disease severity, response to therapy, age, and co‑existing medical conditions. Physicians typically start with a low dose and adjust gradually to achieve optimal symptom control while minimizing side effects.

Safety data in pregnancy and lactation are limited. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Levodopa/Carbidopa is considered the most effective dopaminergic therapy for motor symptom control, whereas dopamine agonists or MAO‑B inhibitors are often used as adjuncts or early‑stage options. Levodopa provides stronger symptomatic relief but may be associated with motor complications such as dyskinesia over long‑term use.

Store the tablets at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in humid or excessively hot environments.

Levodopa/Carbidopa is taken orally, usually with a glass of water. It can be taken with or without food, although high‑protein meals may interfere with absorption. Patients should follow the dosing schedule prescribed by their clinician and avoid crushing or chewing the tablets unless directed otherwise.

Serious risks include the development of dyskinesia (involuntary movements), neuroleptic malignant syndrome, severe psychiatric disturbances such as hallucinations or depression, and rare cardiac arrhythmias. Prompt medical attention is required if any of these symptoms emerge.

Patients with known hypersensitivity to levodopa, carbidopa, or any excipients should avoid the product. It is also contraindicated in individuals taking non‑selective MAO inhibitors, those with narrow‑angle glaucoma, or patients with severe cardiovascular disease unless specifically advised by a physician.